Effect of isopropyl methylphosphonofluoridate (IMPF) poisoning on selected immunological parameters of angiogenesis
More details
Hide details
Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland
Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Health Services, Warsaw, Poland
Biological Threat Identification and Countermeasure Centre, Military Institute of Hygiene and Epidemiology, Puławy, Poland
Department of Pharmacology and Toxicology, Military Institute of Hygiene and Epidemiology, Warsaw, Poland; Jozef Piłsudski University of Physical Education, Warsaw, Poland
Ann Agric Environ Med. 2014;21(4):733–738
introduction and objective. Acetylcholinesterase (AChE) and cholinergic receptors play an important role in the immune system, including lymphocyte-induced angiogenesis. However, their exact role is not fully understood. The presented work tests the influence of isopropyl methylphosphonofluoridate (IMPF), an irreversible inhibitor of AChE, on selected immune parameters associated with angiogenesis in mice. The levels of VEGF, bFGF, TNF-α, and IFN-γ production were measured, together with the ability of lymphoid spleen cells to induce local GvH reaction after a single dose of IMPF. materials and method. Experiments were performed in male BALB/c mice. Acetylcholinesterase activity in erythrocytes was determined by the Ellman`s procedure. Levels of cytokines were measured in serum using standard commercial ELISA kits. Influence of IMPF intoxication upon angiogenesis was examined by the LIA test, according to the Sidky and Auerbach procedure. results. The results showed a 6- and 8-fold increase in VEGF at days 1 and 7 of the experiment, respectively, as well as a decrease (at days 14 and 21 after administration), followed by a significant increase (day 1) in bFGF levels. A statistically significant decrease in the concentration of IFN-γ was observed throughout all experiments. The maximum decrease in the level of TNF-α was found at days 1 and 7 after administration of IMPF. Additionally, a significant decrease was found in the ability to form new blood vessels following IMPF administration. conclusions. This study revealed that IMPF has a significant effect on the regulation of lymphocyte-induced angiogenesis, which is related with the modulation of angiogenic and pro-inflammatory cytokines secretion. The observed differences suggest a possible derangement of certain elements of the neuronal and/or non-neuronal cholinergic system.
Ader R, Felten D, Cohen N. Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol. 1990; 30: 561–602.
Black P. Central nervous system – immune system interactions: psychoneuroendocrinology of stress and its immune consequences. Antimicrob Agents Hemother. 1994; 38(1): 1–6.
Lutz W, Tarkowski M, Dudek B. Psychoneuroimmunologia. Nowe spojrzenie na funkcjonowanie układu odpornościowego. Med Pracy. 2001; 52(3): 203–209 (in Polish).
Jegliński W. Mózg a układ odpornościowy. In: Górska T, Grabowska A, Zagrodzka J (ed.). Mózg a zachowanie. Wydawnictwo naukowe PWN, Warsaw 2005 (in Polish).
Blalock J. The immune system as the sixth sense. J Intern Med. 2005; 257(2): 126–138.
Ganea D, Delgado M. Inhibitory neuropeptide receptors on macrophages. Microbes Infect. 2001; 3(2): 141–147.
Wessler I, Kirkpatrick CJ. Acetylcholine beyond neurons: the nonneuronal cholinergic system in humans. Br J Pharmacol. 2008; 154(8): 1558–1571.
Gołąb J, Jakóbisiak M, Lasek W. Immunologia. Wydawnictwo Naukowe PWN, Warsaw 2004 (in Polish).
Maśliński W. Cholinergic receptors of lymphocytes. Brain Behav Immun. 1989; 3(1): 1–14.
Kawashima K, Yoshikawa K, Fujii YX, Moriwaki Y, Misawa H. Expression and function of genes encoding cholinergic componentsin murine immune cells. Life Sci. 2007; 80(24–25): 2314–2319.
Skok MV, Grailhe R, Agenes F, Changeux JP. The role of nicotinic receptors in B-lymphocyte development and activation. Life Sci. 2007; 80(24–25): 2334–2336.
Zdanowski R, Krzyżowska M, Ujazdowska D, Lewicki S, Stankiewicz W, Skopińska-Różewska E, et al. Th1/Th2 response after isopropyl methylphosphonofluoridate intoxication. Centr Eur J Immunol. 2012; 37(3): 1–5.
Heeschen C, Weis M, Aicher A, Dimmeler S, Cooke J. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J Clin. Invest. 2002; 110(4): 527–536.
Wessler I, Kirkpatrick C. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm Pharmacol Ther. 2001; 14(6): 423–434.
Li J, Chen H. The non-neuronal cholinergic system in immunocompetent cells. Progress in physiology. 2005; 36(3): 193–198.
Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious disease. FEMS Immunol Med Microbiol. 2006; 47(3): 330–342.
Knusel B, Michel P, Schwaber J, Hefti F. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, basic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors I and II. J Neurosci. 1990; 10(2): 558–570.
Monteiro-Riviere N, Baynes R, Riviere J. Pyridostigmine bromide modulates topical irritant-induced cytokine release from human epidermal keratinocytes and isolated perfused porcine skin. Toxicology 2003; 183(1–3): 15–28.
Johnson EA, Kan RK. The acute phase response and soman-induced status epilepticus: temporal, regional and cellular changes in rat brain cytokine concentrations. J Neuroinflammation. 2010; 7: 40. doi: 10.1186/1742–2094–7–40.
Starec M, Sinet M, Kodym P, Rosina J, Fiserova A, Desforges B, et al. The effect of drugs on the mortality of mice inoculated with Friend leukaemia virus or Toxoplasma gondii. Physiol Res. 1997; 46(2): 107–111.
Lennon V, Ermilov L, Szurszewski J, Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin. Invest. 2003; 111(6): 907–913.
Chitnis T, Salama A, Grusby M, Sayegh M, Khoury S. Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol. 2004; 172(7): 4260–4265.
Ellman G, Courtney D, Andres V, Featherstone R. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmac. 1961; 7: 88–95.
Hadar E, Ershler W, Kreisle R, Ho S, Volk M, Klopp R. Lymphocyteinduced angiogenesis factor is produced by L3T4+ murine T lymphocytes, and its production declines with age. Cancer Immunol Immunother. 1988; 26(1): 31–34.
Pietrosiuk A, Skopińska-Różewska E, Furmanowa M, Wiedenfeld H, Sommer E, Sokolnicka I, et al. Immunomodulatory effect of shikonin derivatives isolated from Lithospermum canescens on cellular and humoral immunity in Balb/c mice. Pharmazie. 2004; 59(8): 640–642.
Sidky Y, Auerbach R. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-versus host reaction. J Ex Med. 1975; 141(5): 1084–100.
Skopińska-Różewska E, Piazza G, Sommer E, Pamukcu R, Barcz E, Filewska M, et al. Inhibition of angiogenesis by sulindac and its sulfone metabolite (FGN-1): A potential mechanism for their antineoplastic properties. Int J Tissue React. 1998; 20(3): 85–89.
Kapka-Skrzypczak L, Cyranka M, Skrzypczak M, Kruszewski M. Biomonitoring and biomarkers of organophosphate pesticides exposure – state of the art. Ann Agric Environ Med. 2011; 18(2): 294–303.
Gore A, Brandeis R, Egoz I, Peri D, Turetz J, Bloch-Shilderman E. Efficacy assessment of various anticholinergic agents against topical sarin-induced miosis and visual impairment in rats. Toxicol Sci. 2012; 126(2): 515–524.
Tripathi H, Dewey W. Comparison of the effects of diisopropylfluorophosphate, sarin, soman and tabun on toxicity and brain acetyloholinoesterase activity in mice. J Toxicol Environ Health. 1989; 26(4): 437–446:.
Zajtchuk R (eds.). Medical aspects of chemical and biological warfare. USA: Office of The Surgeon General of the Army, USA. 1997.
Kostowski W. Farmakologia. Wydawnictwo Lekarskie PZWL, Warszawa 1998 (in Polish).
Little P, Scimeca J, Martin B. Distribution of [3H] diisopropylfluorophosphate, [3H] soman, [3H] sarin, and their metabolites in mouse brain. Drug Metab Dispos. 1988; 16(4): 515–520.
Henderson R, Barr E, Blackwell W, Clark C, Conn C, Kalra R, et al. Response of rats to low levels of sarin. Toxicol Appl Pharmacol. 2002; 184(2): 67–76.
Blalock J. Harnessing a neural-immune circuit to control inflammation and shock. J Exp. Med. 2002; 195(6): 25–28.
Fix J. Neuroanatomia. Urban & Partner, Warsaw 1997.
Henderson R, Barr E, Blackwell W, Clark C, Conn CA, Kalra R, et al. Response of F344 rats to inhalation of subclinical levels of sarin: exploring potential causes of Gulf War illness. Toxicol Ind Health. 2001; 17(5–10): 294–297.
Bany J, Zdanowska D, Kowalczyk M. Examination of proinflammatory cytokines: Interleukin-1β, Interleukin-6, and tumor necrosis factor-α in mice after acute isopropyl ester methylphosphonofluoridate (IMPF) poisoning. Pol J Environ Stud. 2005; 14: 14–18.
Sainson RC, Johnston DA, Chu HC, Holderfield MT, Makatsu MN, Crampton SP, et al. TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype. Blood. 2008; 111(10): 4997–5007.
Arias HR, Richards VE, Ng D, Ghafoori ME, Le V, Mousa SA. Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis. Int J Biochem Cell Biol. 2009; 41(7): 1441–1451.
Eldad A, Burt A, Clarke J, Gusterson B. Cultured epithelium as a skin substitute. Burns Incl Therm Inj. 1987; 13(3): 173–180.
Leeuwenberg J, Van Damme J, Meager T, Jeunhomme T, Buurman W. Effects of tumor necrosis factor on the interferon-gamma-induced major histocompatibility complex class II antigen expression by human endothelial cells. Eur J Immunol. 1988; 18(9): 1469–1472.
Mor F, Quintana F, Cohen I. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol. 2004; 172(7): 4618–4623.
Piguet P, Janin-Mercier A, Vassalli P, Saurat J. Epidermal lesions of the GVHR: evaluation of the role of different MHC and non MHC loci and of the Ly-2+ and L3T4+ T lymphocytes. J Immunol. 1987; 139(2): 406–410.
Herve P, Bordigoni P, Plouvier E. Chemotherapy versus allogeneic or autologous bone marrow transplantation in second complete remission of acute lymphoblastic leukemia. Leukemia. 1992; 6(4): 59–61.
McKenzie R, Oran A, Dinarello C, Sauder D. Interleukin-1 receptor antagonist inhibits subcutaneous B16 melanoma growth in vivo. Anticancer Res. 1996; 16(1): 437–441.
Yamamoto S, Tsuji T, Matsuzaki J, Zhange Y, Chamoto K, Kosaka A, et al. Unexpected role of TNF-alpha in graft versus host reaction (GVHR): donor-derived TNF-alpha suppresses GVHR via inhibition of IFN-gamma-dependent donor type-1 immunity. Int Immunol. 2004; 16(6): 811–817.
Kassa J, Krocova Z, Sevelova L, Sheshko V, Kasalova I, Neubauerova V. Low-level sarin-induced alteration of immune system reaction in inbred BALB/c mice. Toxicology 2003; 187(2–3): 195–203.
Kassa J, Krocova Z, Sevelova L, Sheshko V, Kasalova I, Neubauerova V. The influence of single or repeated low-level sarin exposure on immune functions of inbred BALB/c mice. Basic Clin Pharmacol Toxicol. 2004; 94(3): 139–143.
Bany J, Zdanowska D. Działanie neuroimmunomodulujące wysokotoksycznego związku fosforoorganicznego na rozwój infekcji pasożytniczej. Wiad Parazyt. 2004; 50, 135–141 (in Polish).
Peña-Philippides JC, Razani-Boroujerdi S, Singh SP, Langley RJ, Mishra NC, Henderson RF, et al. Long- and short-term changes in the neuroimmune-endocrine parameters following inhalation exposures of F344 rats to low-dose sarin. Toxicol Sci. 2007; 97(1): 181–188.
Kalra R, Singh S, Razani-Boroujerdi S, Langley R, Blackwell W, Henderson R, et al. Subclinical doses of the nerve gas sarin impair T cell responses through the autonomic nervous system. Toxicol Appl Pharmacol. 2002; 184(2): 82–87.
Madden K, Felten S, Felten D, Sundaresan P, Livnat S. Sympathetic neural modulation of the immune system. I. Depression of T cell immunity in vivo and vitro following chemical sympathectomy. Brain Behav Immun. 1989; 3(1): 72–89.
Kruszewska B, Felten D, Stevens S, Moynihan J. Sympathectomyinduced immune changes are not abrogated by the glucocorticoid receptor blocker RU-486. Brain Behav Immun. 1998; 12(3): 181–200.